<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149525">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01716988</url>
  </required_header>
  <id_info>
    <org_study_id>NL39246.042.12</org_study_id>
    <nct_id>NCT01716988</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Micafungin in Critically Ill Patients</brief_title>
  <official_title>Pharmacokinetics of Micafungin in Critically Ill Patients With Invasive Candidiasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Centre Groningen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Medical Centre Groningen</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study of micafungin in ICU versus non-ICU patients showed a significantly lower treatment
      success in ICU patients compared with non-ICU patients. It is known that in critically ill
      patients, alterations in function of various organs and body systems can influence the
      pharmacokinetics and hence the plasma concentration of a drug. The pharmacokinetic
      parameters of micafungin in critically ill patients are most likely different, but this has
      not been specifically studied.

      The pharmacokinetic parameters of micafungin in critically ill patients will be established
      and plasma concentrations of micafungin will be correlated with disease severity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">November 2014</completion_date>
  <primary_completion_date type="Anticipated">September 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Correlation of pharmacokinetic parameters/plasma concentrations of micafungin with disease severity.</measure>
    <time_frame>4 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Correlation of the level of micafungin concentration with disease severity scores. Correlation of pharmacokinetic parameters (clearance, half-life) of micafungin with disease severity scores.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic parameters of micafungin in ICU patients.</measure>
    <time_frame>4 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Calculate the pharmacokinetic parameters (clearance, half life, volume of distribution) of micafungin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time (in days) to culture conversion.</measure>
    <time_frame>max 28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Number of days untill cultures are negative.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of the plasma concentration of micafungin with response to treatment.</measure>
    <time_frame>max 28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Correlation of the level of micafungin concentration with outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation of the plasma concentration of micafungin with inflammation parameters.</measure>
    <time_frame>4 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Correlation of the level of micafungin concentration with interleukin-6, interleukin-8 and procalcitonin.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC)/minimal inhibitory concentration (MIC) ratio.</measure>
    <time_frame>max 28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Area under the concentration-time curve of micafungin devided by the minimal inhibitory concentration of the candida species.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Composing a pharmacokinetic model of micafungin in critically ill patients.</measure>
    <time_frame>max 28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Composing a pharmacokinetic model of micafungin to estimate the 24-hours AUC of micafungin based on limited samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Highest observed plasma concentration (Cmax)/minimal inhibitory concentration (MIC) ratio.</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
    <description>Highest observed plasma concentration of micafungin devided by the minimal inhibitory concentration of the candida species.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Critical Illness</condition>
  <condition>Invasive Candidiasis</condition>
  <arm_group>
    <arm_group_label>Micafungin</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with invasive candidiasis admitted to an intensive care unit.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Treatment with micafungin.

          -  Admission to an ICU.

          -  Age â‰¥ 18 years.

          -  Invasive candidiasis.

        Exclusion Criteria:

          -  Blood sampling not possible.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Medical Center Groningen</name>
      <address>
        <city>Groningen</city>
        <zip>9700 RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J WC Alffenaar, PharmD, PhD</last_name>
      <phone>0031503614070</phone>
      <email>j.w.c.alffenaar@umcg.nl</email>
    </contact>
    <investigator>
      <last_name>J WC Alffenaar, PharmD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 29, 2014</lastchanged_date>
  <firstreceived_date>October 8, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Centre Groningen</investigator_affiliation>
    <investigator_full_name>JWC Alffenaar</investigator_full_name>
    <investigator_title>PharmD, PhD</investigator_title>
  </responsible_party>
  <keyword>Micafungin</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>invasive candidiasis</keyword>
  <keyword>intensive care</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Critical Illness</mesh_term>
    <mesh_term>Candidiasis, Invasive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Micafungin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
